Recent research has found that the popular GLP-1 medication, Mounjaro, may help lower heart attack risk in people with type 2 diabetes. Galina Zhigalova · Moment/Getty

New research suggests the GLP-1 medication Mounjaro may lower the risk of heart attack and other major cardiovascular events in people with type 2 diabetes and established heart disease.

Researchers estimated that for every 70 people who started tirzepatide, one major cardiovascular event could be prevented.

The findings suggest tirzepatide may provide cardiovascular benefits when added to standard type 2 diabetes care.

New research suggests the popular GLP-1 medication Mounjaro may lower the risk of major cardiovascular events, including heart attack, in people with type 2 diabetes and established heart disease.

Previous randomized trials have shown that, compared with dulaglutide (Trulicity), tirzepatide (Mounjaro) had similar effects on major cardiovascular events.

Major cardiovascular events are a combined measure of heart attack, stroke, and death from any cause.

For the new study, researchers analyzed health insurance data from nearly 53,000 people with type 2 diabetes, overweight or obesity, and established heart disease. They compared cardiovascular outcomes among people taking tirzepatide with those taking sitagliptin, another diabetes medication.

The results were published August 5 in The BMJ. 

Mounjaro may lower heart attack risk by 33%

The analysis included 52,971 individuals with an average age of 70. Of those, 35,353 started tirzepatide, and 17,618 started sitagliptin. 

Sitagliptin was chosen as a placebo proxy based on previous studies showing no effect on cardiovascular outcomes. 

The researchers focused on the risk of major cardiovascular events. This was monitored for 1 year or until an individual stopped or switched treatment, or disenrolled from the health insurance plan. 

They took into account factors including: 

age

sex

race

BMI

previous heart issues

other chronic conditions

other medication use

At the one-year mark, the risk of major cardiovascular events was 2.9% in the tirzepatide group and 4.4% in the sitagliptin group. The researchers estimated that for every 70 individuals starting tirzepatide, one major cardiovascular event could be prevented.

Taking into account the individual components of major cardiovascular events, tirzepatide was associated with a 33% reduction in heart attacks compared with sitagliptin. There was no meaningful difference for ischemic stroke. 

The tirzepatide group also saw reductions in the following areas: 

infections requiring hospitalization (1 admission prevented for every 48 people)

deaths from infection (1 death prevented for every 200 people)

death from any cause (1 death prevented for every 122 people)

“These findings build on a growing body of research showing that GLP-1 medications can benefit more than just blood sugar; they may also support heart health and help manage conditions like diabetes and cardiovascular disease,” Cheng-Han Chen, MD, board certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA, who wasn’t involved in the study, said. 

However, the researchers noted that the study was observational and had a relatively short follow-up period, and additional research is needed to confirm the findings.

Who may benefit from Mounjaro?

“Tirzepatide does not currently have FDA approval for cardiac risk reduction, and thus, coverage and usage are limited to patients with type 2 diabetes, obesity, and obstructive sleep apnea,” said David Rhee, MD, board certified cardiologist with Manhattan Cardiology in NYC, who wasn’t involved in the study. 

Mounjaro is currently only approved for the treatment of type 2 diabetes.  

Zepbound has the same active ingredient, tirzepatide, and is approved for weight loss.

If you have questions about GLP-1 medications and how they may help improve your health, speak with a healthcare professional. 

How Mounjaro may support cardiovascular health

Chen told Healthline that GLP-1s like Mounjaro can help improve heart health in a couple of important ways. They can help manage major risk factors, such as blood sugar, weight, and blood pressure. 

GLP-1s can also directly support the heart and blood vessels by reducing inflammation and improving circulation, said Chen.  

Tirzepatide, the active ingredient in Mounjaro, works by mimicking two natural gut hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This helps lower blood sugar and supports your body in making more insulin, if needed. It can also slow digestion, which can help keep blood sugar levels under control after eating.

However, most data on GIP’s role in cardiovascular disease is preclinical and is still under investigation. 

“GLP-1 receptor agonists are quickly becoming a common part of treatment for people with diabetes and those at higher risk for heart disease. As more people use these medications, we may continue to see broader benefits for overall heart health,” said Chen.

“The writing is on the wall. Science, industry, and politics are adapting quickly. The effect that this class of medications will have on our public health cannot be overstated,” said Rhee. 

(MedPage Today) — More than 150 deaths possibly linked to injectable weight-loss medications were reported in the U.K., according to government regulators. (The Independent)
Texas Children’s Hospital in Houston will open the nation’s first detransition…

(MedPage Today) — GLP-1 drugs, used for type 2 diabetes and weight loss, have been touted for their many benefits, but it’s their side effects that often make headlines, especially those with compelling monikers like “Ozempic teeth.”
Here, we…

(MedPage Today) — Shanghai-based biotech company HuidaGene Therapeutics disclosed the death of a child 1 year ago in a trial of an investigational gene-editing therapy for Duchenne muscular dystrophy.
Semaglutide (Wegovy) attenuated a proteomics…

Medicare’s new weight loss drug program “risks creating barriers at precisely the moment when confidence in broader GLP‑1 coverage is most needed,” writes Jeffrey Millstein.

Tuesday, August 11 – GLP-1 drugs like Mounjaro may help lower heart attack risk by 33%.

Tuesday, August 11 – For decades, obesity medications produced only modest weight loss. But in recent years, Ozempic and related GLP-1 therapies have transformed the field, enabling sustained weight loss of 10% to 15% or more. Despite their success, however, scientists have not fully understood how these drugs work in the brain.

Tuesday, August 11 – An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks. Unlike injectable drugs such as Wegovy and Ozempic, aleniglipron is a small molecule that can be taken once daily with or without food and could potentially be produced more easily at scale.

Tuesday, August 11 – Chrissy Metz joins TODAY’s Jenna Bush Hager and Sheinelle Jones to talk about her journey with GLP-1s and becoming a spokesperson for Ro. She opens up about struggling with her weight as a child, dealing with “food noise,” and making healthy changes to her lifestyle. She shares how GLP-1s have improved her life and says she “wouldn’t be able to do 8 shows a week” without them. Then, she talks about having a supportive partner and the 10 year anniversary of “This Is Us.”

Monday, August 10 – GLP-1 medications may help lower fragility-related fracture risk in people with type 2 diabetes. OLEKSANDRA TROIAN · Moment/Getty

A new study found that GLP-1 medications may help reduce the risk of fragility fractures in people with type 2 diabetes.

Sunday, August 9 – A heads-up to anyone on medications like Ozempic, Wegovy, Zepbound and more.View Entire Post ›

Sunday, August 9 – Eli Lilly and Co. fired off a round of lawsuits in Delaware federal court seeking to block generic versions of its tirzepatide weight loss and diabetes medications, targeting Sandoz, MSN Laboratories and others.

Friday, August 7 – In our series “The Cost of Denial” NBC News’ Liz Kreutz reports on the debate over when and how to cover popular weight loss drugs, especially after a patient sheds the pounds. Should GLP-1s be covered as maintenance drugs?

Friday, August 7 – A legal dispute between the FDA and Eli Lilly over whether the highly anticipated obesity candidate retatrutide is indeed a biologic has come to a head as the company prepares to submit the medicine for approval.

Friday, August 7 – Another quarter, another battle on the GLP-1 front. This time, the winner seems to be Eli Lilly and Co., which reported a 48% increase in second-quarter sales driven primarily by tirzepatide drugs Zepbound and Mounjaro for diabetes and obesity drugs, blowing past analyst expectations. Though also disclosing impressive numbers, Novo Nordisk A/S found investors focusing on sales of its pill version of Wegovy (semaglutide), which fell short of analyst estimates for the three months ending June 30.

Friday, August 7 – A Texas federal judge has denied Revive Rx’s bid to end Eli Lilly and Co.’s remaining unfair competition claims over the compounding pharmacy’s sales of allegedly unapproved tirzepatide weight loss drugs that Eli Lilly says compete with Mounjaro and Zepbound, rejecting Revive’s argument that compounded drugs fall outside state “new drug” laws.

Thursday, August 6 – Eli Lilly’s shares rose nearly 5% to $1,170 apiece in premarket trading as the company reported $23 billion in revenue for the second quarter. The company’s market cap is $1.02 trillion as of the end of July.

Thursday, August 6 – Amgen has discontinued Phase 1 obesity candidate AMG 513, leaving MariTide as its sole weight loss asset. Meanwhile, executives said the company’s late-stage pipeline is largely full and future business development will focus on earlier-stage opportunities.

Thursday, August 6 – As the use of GLP-1 and other incretin-based medications for obesity continues to grow worldwide, researchers at Marshall University have contributed to an international effort to address one of medicine’s most pressing unanswered questions: How should these medications be used by women before, during and after pregnancy?

Thursday, August 6 – Novo Nordisk’s shares fell 6% on Tuesday afternoon after its second quarter earnings report showed a slight miss for the Wegovy pill vs. consensus.

Wednesday, August 5 – (MedPage Today) — The American Diabetes Association (ADA) asked for patience as its Audit and Governance Committee reviews the incident at this year’s annual meeting — when five prominent experts were removed by police — and prepares recommendations…

Wednesday, August 5 – (MedPage Today) — Retatrutide Access Expanded

Wednesday, August 5 – A heads-up to anyone on medications like Ozempic, Wegovy, Zepbound and more.

Tuesday, August 4 – (MedPage Today) — GLP-1 Temporal Hollowing

Tuesday, August 4 – (MedPage Today) — Bariatric surgery has long been considered the gold standard for treating obesity. However, with weight-loss medications like GLP-1 receptor agonists skyrocketing in popularity, fewer patients are choosing surgery.
According…

Monday, August 3 – As food becomes less stimulating, GLP-1 users are gravitating toward this instead.View Entire Post ›

Sunday, August 2 – (MedPage Today) — Note that some links may require registration or subscription.
Ahman Green, 49, a four-time NFL Pro Bowl running back and the Green Bay Packers’ career rushing leader, has Parkinson’s disease. (AP)
In other NFL news, former…

Friday, July 31 – This is the reality TikTok won’t show you.

Thursday, July 30 – GLP-1 drugs linked to temporary hair loss: Here’s why

Thursday, July 30 – Shareholders allege that Novo Nordisk withheld information about crucial protocol changes in a Phase 3 study of the weight loss drug CagriSema, which led investors to buy company shares “at artificially inflated prices.”

Wednesday, July 29 – (MedPage Today) — Major Pharmaceuticals issued a nationwide recall of multiple doses of levothyroxine sodium tablets, sold under the Major and Cardinal brands, due to subpotency. (USA Today)
The investigational triple agonist retatrutide met…

Wednesday, July 29 – GLP-1 medications such as Ozempic have transformed the treatment of type 2 diabetes, helping millions of patients better control their blood sugar while reducing cardiovascular risk and, for many, promoting substantial weight loss.

Wednesday, July 29 – Pemvidutide showed a “highly statistically significant” treatment effect in patients with alcohol use disorder. Altimmune is going up against Eli Lilly and newcomer Baseline Therapeutics, among others, in this space.

Wednesday, July 29 – Despite the president’s comments, patients say these medications have been life-changing, and their effectiveness cannot be ignored.

Tuesday, July 28 – Can GLP-1s increase the risk of a rare eye condition?

Tuesday, July 28 – Different varieties and doses of GLP-1 medications can have meaningful differences in how they address heart and metabolic health issues, according to new research led by the Perelman School of Medicine at the University of Pennsylvania. Through an analysis of data from 19 randomized controlled trials, the researchers believe their work points to possible precision medicine applications of GLP-1s beyond weight loss. Their work is published in Diabetes, Obesity, and Metabolism.

Tuesday, July 28 – (MedPage Today) — Note that some links may require registration or subscription.
More healthcare workers in Congo went on strike as confirmed Ebola cases in the nation approached 3,000, including 1,309 deaths. (AP)
Florida reported the state…

Sunday, July 26 – Recent research has found that GLP-1s, like Ozempic and Wegovy, can help you maintain a lower calorie intake for more than a year. Image Credit: Jon Challicom/Getty

A new study found that people taking semaglutide (Ozempic and Wegovy) maintained a significantly lower calorie intake after 60 weeks on the medication.

Participants taking semaglutide consistently consumed 24% to 30% fewer calories than those receiving a placebo throughout the study.

The findings suggest semaglutide may continue supporting weight loss even after differences in hunger and food cravings begin to fade.